Scholar Rock (SRRK) stock soared on Friday after the biotechnology company released its Q3 2025 earnings report. The company reported earnings per share of -90 cents, compared to Wall Street’s estimate of -84 cents. Investors will also note that the company’s EPS widened 36.36% year-over-year from -66 cents.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Scholar Rock stated that it didn’t report any revenue in the third quarter of 2025, though analysts expected revenue of $56,000 during the period. It’s also worth pointing out that the company didn’t report any revenue in the same period of the year prior.
The lackluster Q3 earnings report may have some investors wondering why SRRK stock rallied today. This movement is tied to a meeting the company had with the U.S. Food and Drug Administration (FDA) earlier this week. On Wednesday, Scholar Rock had a Type A meeting with the FDA concerning its SMA program. It called the meeting “constructive” and said it has made progress on its remediation plan. The company expects its facility to be ready for reinspection by the end of the year, with a planned resubmission of its BLA for adults with SMA in 2026.
Scholar Rock Stock Movement Today
Scholar Rock stock was up 22.78% on Friday but remained down 14.58% year-to-date. Even so, the shares have rallied 13.51% over the past 12 months.
Despite today’s rally, trading of SRRK stock remained muted. Only about 42,000 shares have changed hands, compared to a three-month daily average of about 2.66 million units.
Is Scholar Rock Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Scholar Rock is Strong Buy, based on 11 Buy ratings over the past three months. With that comes an average SRRK stock price target of $46.67, representing a potential 27.37% upside for the shares. These ratings and price targets will likely change as analysts update their coverage after today’s earnings report.
